Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study
Juan Pablo Arab,Luis Antonio Díaz,Natalia Baeza,Francisco Idalsoaga,Eduardo Fuentes-López,Jorge Arnold,Dalia Morales-Arraez,Meritxell Ventura-Cots,Edilmar Alvarado-Tapias,Wei Zhang,Virginia Clark,Douglas Simonetto,Seth Buryska,Horia Stefanescu,Adelina Horhat,Andreea Bumbu,Winston Dunn,Bashar Attar,Rohit Agrawal,Zohaib Syed Haque,Muhammad Majeed,Joaquín Cabezas,Inés García-Carrera,Richard Parker,Berta Cuyàs,Maria Poca,German Soriano,Rakhi Maiwall,Saba Abdulsada,María Fátima Higuera-de la Tijera,P Nagaraja Rao,Patricia Guerra Salazar,Lubomir Skladaný,Natália Bystrianska,Veronica Prado,Ana Clemente-Sanchez,Diego Rincón,Tehseen Haider,Fernando Cairo,Marcela de Sousa Coelho,Juan Carlos Restrepo,Susana Castro-Sanchez,Pamela Yaquich,Manuel Mendizabal,Maria Laura Garrido,Adrián Narvaez,Fernando Bessone,Julio Santiago Marcelo,Diego Piombino,Melisa Dirchwolf,Juan Pablo Arancibia,José Altamirano,Won Kim,Andrés Duarte-Rojo,Victor Vargas,Pierre-Emmanuel Rautou,Tazime Issoufaly,Felipe Zamarripa,Aldo Torre,Philippe Mathurin,Alexandre Louvet,Guadalupe García-Tsao,José Alberto González,Elizabeth Verna,Juan Pablo Roblero,Marco Arrese,Ramon Bataller,Carolina A. Ramírez,Joseph C. Ahn,Tej I. Mehta,Shiv K. Sarin,Prasun K. Jalal,Anand V. Kulkarni,Kristina R. Chacko,Gustavo A. Romero,Florencia D. Pollarsky,Luis G. Toro,Roberta C. Araujo,Michael R. Lucey,Robert S. Brown,Juan G. Abraldes,Vijay H. Shah,Patrick S. Kamath,Ashwani K. Singal
DOI: https://doi.org/10.1016/j.jhep.2021.06.019
IF: 25.7
2021-11-01
Journal of Hepatology
Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS">Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score &gt;20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH.</AbstractText>METHODS: <AbstractText Label="METHODS">We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method.</AbstractText>RESULTS: <AbstractText Label="RESULTS">In our cohort, median age was 49 (40-56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19-29). Survival was 88% (87-89) at 30 days, 77% (76-78) at 90 days, and 72% (72-74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47-0.74; p &lt;0.001). Steroids only improved survival in patients with MELD scores between 21 (HR 0.61; 0.39-0.95; p = 0.027) and 51 (HR 0.72; 0.52-0.99; p = 0.041). The maximum effect of corticosteroid treatment (21-30% survival benefit) was observed with MELD scores between 25 (HR 0.58; 0.42-0.77; p &lt;0.001) and 39 (HR 0.57; 0.41-0.79; p &lt;0.001). No corticosteroid benefit was seen in patients with MELD &gt;51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247).</AbstractText>CONCLUSION: <AbstractText Label="CONCLUSION">Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39.</AbstractText>LAY SUMMARY: <AbstractText Label="LAY SUMMARY">Alcohol-associated hepatitis is a condition where the liver is severely inflamed as a result of excess alcohol use. It is associated with high mortality and it is not clear whether the most commonly used treatments (corticosteroids) are effective, particularly in patients with very severe liver disease. In this worldwide study, the use of corticosteroids was associated with increased 30-day, but not 90- or 180-day, survival. The maximal benefit was observed in patients with an MELD score (a marker of severity of liver disease; higher scores signify worse disease) between 25-39. However, this benefit was lost in patients with the most severe liver disease (MELD score higher than 51).</AbstractText>
gastroenterology & hepatology